Pfizer Reports Positive Phase 2 Results for Trispecific Antibody in Moderate-to-Severe Atopic Dermatitis Pfizer Inc. today announced positive topline results from a Phase 2 study investigating tilrekimig (PF-07275315) in adults with moderate to severe atopic dermatitis. The study met its…
Response Pharmaceuticals Reports Positive 36-Week Phase 2 Data Supporting RDX-002 as a Long-Term Option in Post-GLP-1 Receptor Agonist Weight Management Response Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing therapies for weight management and metabolic health, reinforces its position as a…
Liberate Bio Secures Myeloid-Optimized CAR Design Licenses to Advance In Vivo CAR-M Programs Liberate Bio, Inc., a biotechnology company developing genetic medicines that deliver RNA therapies directly to immune cells, announces that it has secured exclusive and non-exclusive licenses to…
FUJIFILM Biotechnologies Unveils ShunzymeX™ Precision Purification Technology FUJIFILM Biotechnologies, a world leading contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, today unveils ShunzymeX precision purification technology, which simplifies downstream processing for complex biologics. The technology will…
The Progeria Research Foundation and Forge Biologics Announce Manufacturing Partnership to Advance Gene Therapy for Children with Progeria The Progeria Research Foundation (“PRF”), a nonprofit research organization dedicated to developing treatments and the cure for Hutchinson-Gilford Progeria Syndrome (“Progeria”), and…
Roche’s fenebrutinib reaffirms potential as the sole BTK inhibitor for relapsing and primary progressive MS with positive FENhance 1 Phase III results. Roche announced today that the pivotal Phase III study (FENhance 1) of fenebrutinib in RMS met its primary…
Wisdom Bioscience Establishes Scientific Advisory Board to Advance Oral Cancer Diagnostics and Screening Wisdom Bioscience, a biotechnology company revolutionizing oral cancer diagnostics, has announced the formation of its Scientific Advisory Board (SAB) following a successful initial funding round. The SAB…
New Data at ASCO GU Highlights Signatera’s Role in Bladder Preservation and Precision Medicine Why are precision medicine tools crucial for improving patient outcomes in genitourinary cancers? Natera, a global leader in cell-free DNA and precision medicine, is addressing this…
Promising Results for BCG-naïve NMIBC Patients Why are new treatment options for non-muscle invasive bladder cancer (NMIBC) crucial for patient outcomes? ImmunityBio a commercial-stage immunotherapy company, has completed enrollment in its Phase 2 clinical trial evaluating ANKTIVA® plus Bacillus Calmette-Guérin…
Hawks and Ressler Gertz Family Foundation Boost Prostate Cancer Research with $150,000 Donation Why is prostate cancer awareness and research crucial in the sports industry? The Atlanta Hawks Foundation, in partnership with the Ressler Gertz Family Foundation, has announced a…
AdvanCell Unveils Innovative Phase 2 Design for ADVC001 in Metastatic Prostate Cancer Why are new treatment options for metastatic prostate cancer crucial? AdvanCell, a clinical-stage radiopharmaceutical company, is addressing this urgent need with its innovative targeted alpha therapy, ADVC001. Based…
Preclinical Study Shows Targeted Degradation of MYC and KRAS Using Bionic Biologics Platform Why have traditional cancer treatments struggled to target the most aggressive forms of the disease? Grove Biopharma, a private biotechnology company based in Chicago, is addressing this…